Preparedness Study: Efficacy of HPV Vaccine to Reduce HIV Infection
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 406
- 试验地点
- 4
- 主要终点
- Human Papillomavirus (HPV) Rate
研究概览
简要总结
Moffitt Cancer Center is the Coordinating Center for this study.
The purpose of this study is to develop and test the infrastructure to conduct a future Phase III vaccine efficacy trial to assess trial feasibility, and to assess human papillomavirus (HPV) genotype distribution, data needed to design a Phase III trial. The investigators propose to conduct a Preparedness study among women ages 16-24 years of age residing in a region of South Africa with a high human immunodeficiency (HIV) incidence and prevalence.
The specific aims of this study are to:
- Identify, recruit, enroll, and randomize a cohort of HIV negative women (200 per arm, 400 total) ages 16-24 years to an HPV vaccine against 4 types (HPV 6, 11, 16, 18 [Gardasil]) or placebo vaccine.
- Determine the cervical HPV prevalence and type distribution at enrollment, and cervical lesion prevalence among young females ages 16-24 years at high risk for HIV infection.
- Assess the rate of compliance through the 3-dose vaccination series
详细描述
The study vaccine will be blindly administered as supplied on Day 1, Month 2, and Month 6. Both HPV and placebo vaccines will be in identical bottles, and all treatment codes will be kept under lock and key. All vaccines will be injected intramuscularly into the deltoid muscle by a member of the clinical staff. Each participant will be monitored for systemic and local reactions for 30 minutes postvaccination after each study vaccination for any adverse effects, including allergic reactions. Vaccine adverse events will continue to be monitored throughout the duration of the study period. Vaccine will be shipped to a central pharmacy at Stellenbosch University and stored in a refrigerator monitored and maintained at 2-8 C prior to distribution and local storage at participating clinical centers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 16 Years 至 24 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women ages 16-24 years of age residing in a region of South Africa with a high HIV incidence and prevalence
- •HIV negative
- •has ever had vaginal intercourse
- •has never had Papanicolaou smear (Pap) testing or has only had normal Pap test results
- •fully understands study procedures, risks involved in the study, and voluntarily agrees to participate by giving written informed consent
- •agrees to refrain from douching/vaginal cleansing and using vaginal medications or preparations for 2 calendar days prior to the Day 1 visit as well as other future visits that include collection of cervical specimens
- •agrees to refrain from sexual intercourse for 2 calendar days prior to the Day 1 visit as well as other future visits that include collection of cervical specimens
- •agrees to utilize effective contraception during sexual intercourse (excluding the rhythm method, withdrawal alone, and emergency contraception) during the vaccination period.
- •Informed consent procedures for females <18 years of age: Informed consent and informed assent will be obtained from parents/legal guardians and adolescents respectively, prior to participation. The consent form will include information about the study and individual request for consent of participants to participate in the study. It will be emphasized that participation is voluntary and that participants are free to withdraw from the study at any stage without any disadvantage to them. An assessment of understanding will be conducted at screening to ensure that consent is informed.
排除标准
- •have a history of severe allergic reaction
- •have a known allergy to any vaccine component (e.g., aluminum, yeast, or BENZONASE)
- •are currently immuno-compromised
- •have received a marketed HPV vaccine, or are pregnant and lactating
研究组 & 干预措施
Gardasil Vaccine Administration
Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
干预措施: Gardasil Vaccine (Biological)
Placebo Administration
Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
干预措施: Placebo (Other)
结局指标
主要结局
Human Papillomavirus (HPV) Rate
时间窗: At Enrollment - 5 Month Enrollment Period
HPV type distribution and prevalence of each HPV type at enrollment.
次要结局
- Percentage of Participants Who Seroconverted to HPV Types 31, 33, 45, or 58(18 Months)
- Study Compliance Rate(18 Months)
- Percentage of Participants Who Were Seropositive by HPV Type(At Enrollment - 5 Month Enrollment Period)
- Percentage of Participants Seroconverted to HPV Types 6, 11, 16, or 18(18 Months)